Product Information
OCTREOTIDE 1,000 MCG/5 ML VIAL is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $5.3404 per ML under NDC 00641617701. Its NADAC has been published 146 times since Jan 22, 2020.
FDA first approved this application on Apr 8, 2005. Its Orange Book therapeutic-equivalence code is AP.
Strength
200 ug/mL
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00641617701
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
4/22/2026
Active Ingredients
OCTREOTIDE ACETATEApproval Type
Generic (ANDA)
FDA Application
ANDA076330FDA Approved
4/8/2005
TE Code
AP
On Market Since
4/8/2005
Pharmacological Classes
Price Statistics
The NADAC for OCTREOTIDE 1,000 MCG/5 ML VIAL has been published 146 times since Jan 22, 2020, and over the history we have for it it has declined 41.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.3404 per ML |
|---|---|
| All-time high | $9.1972 (Jan 13, 2021) |
| All-time low | $5.0838 (Jan 21, 2026) |
| 52-week high | $5.3404 |
| 52-week low | $5.0838 |
| Median price | $5.9696 |
| Average price | $6.8909 |
| Largest weekly change | -28.9% (Dec 18, 2024) |
| Weeks tracked | 146 |
| Tracking since | Jan 22, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Octreotide Acetate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Octreotide Acetate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Somatostatin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OCTREOTIDE 1,000 MCG/5 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for OCTREOTIDE 1,000 MCG/5 ML VIAL, manufactured by Hikma Pharmaceuticals USA Inc., is $5.3404 per ML (NDC 00641617701), effective Sep 30, 2026.
How has the price of OCTREOTIDE 1,000 MCG/5 ML VIAL changed over time?
Over the history we have for it, the NADAC for OCTREOTIDE 1,000 MCG/5 ML VIAL has declined 41.9%. It has been tracked across 146 weekly CMS publications since Jan 22, 2020.
What are the highest and lowest recorded NADAC prices for OCTREOTIDE 1,000 MCG/5 ML VIAL?
Since Jan 22, 2020, the NADAC for OCTREOTIDE 1,000 MCG/5 ML VIAL has ranged from a low of $5.0838 (Jan 21, 2026) to a high of $9.1972 (Jan 13, 2021), with a median of $5.9696 per ML.
Are there cheaper alternatives to OCTREOTIDE 1,000 MCG/5 ML VIAL?
No other NADAC-published product currently shares the active ingredient and strength of OCTREOTIDE 1,000 MCG/5 ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OCTREOTIDE 1,000 MCG/5 ML VIAL?
OCTREOTIDE 1,000 MCG/5 ML VIAL (NDC 00641617701) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.